C
Citius Oncology, Inc. (CTOR)
0.51
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.51
0.00 (0.00%)
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
| Name | Position |
|---|---|
| Dr. Myron S. Czuczman M.D. | Executive VP & Chief Medical Officer |
| Mr. Jaime Bartushak | Chief Financial Officer & Treasurer |
| Mr. Leonard L. Mazur | CEO, President & Executive Chairman |
| Mr. Myron Z. Holubiak | Secretary & Executive Vice Chairman |
| Date | Type | Document |
|---|---|---|
| 2026-03-10 | 8-K | ea0280663-8k_citius.htm |
| 2026-03-04 | 8-K | ea0277423-8k_citius.htm |
| 2026-01-29 | DEF 14C | ea0274187-def14c_citius.htm |
| 2026-01-05 | S-3 | ea0271642-s3_citius.htm |
| 2025-12-23 | 8-K | ea0270775-8k_citius.htm |
| 2025-12-10 | 8-K | ea0269093-8k_citius.htm |
| 2025-12-01 | 8-K | ea0267560-8k_citius.htm |
| 2025-10-27 | 8-K | ea026265801-8k_citiusonc.htm |
| 2025-10-23 | 8-K | ea0262328-8k_citiusonc.htm |
| 2025-09-26 | DEF 14A | ea0257805-def14a_citius.htm |